Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A (1)H-Magnetic Resonance Spectroscopy Study

BACKGROUND: Antiangiogenic treatment of glioblastomas with Bevacizumab lacks predictive markers. Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality. Since Bevacizumab markedly reduces tumor edema and influences the tumor microe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Autores principales: Steidl, Eike, Pilatus, Ulrich, Hattingen, Elke, Steinbach, Joachim P., Zanella, Friedhelm, Ronellenfitsch, Michael W., Bähr, Oliver
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5198997/
https://ncbi.nlm.nih.gov/pubmed/28033329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0168113
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares